SecBot SecBot

LRMR

Larimar Therapeutics, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001374690 Biotech & Drug Discovery
$3.00 −0.02 (−0.66%)
Nov 16 4:00 PM ET · prev $3.02
Market cap
$280.5M
Micro cap
Median target
🔒 Subscribers only
1 year
−15.0%
from $3.53 · Nov 17
30 days
+41.5%
from $2.12
52-week range
$1.99–5.95
−50% from high · low Oct 16
Avg volume 20D
1.37M
shares / day
Short interest
10.54M
≈10.1% of shares · −28.1%
Days to cover
8.3
at average volume
Insider net
+$26.1M
9 buyers · 0 sellers · 12 mo
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
10
analyzed by SecBot
SecBot read BULLISH 7 reports · 90 days
Balance 1 bearish · 3 bullish · 3 neutral oldest → newest, height = score
Avg score ·High conf. 3/7

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBULLISH

    9 insiders bought $26.1M at an average $4.92. No open-market sales. Price is 39% below their cost.

  • InstitutionsBEARISH

    Q3 2026: 13 added (0 new), 21 trimmed or exited.

  • Short sellersCOVERING

    Short interest −28.1% to 10.54M shares. 8.3 days to cover, ≈10.1% of shares.

  • TrendUPTREND

    3% above its 50-day average.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
UBS Group AGADD216,387$691.4K
MORGAN STANLEYDOUBLED213,988$683.7K
FEDERATED HERMES, INC.DOUBLED189,065$604.1K
RENAISSANCE TECHNOLOGIES LLCTRIM184,043$588.0K
Creative PlanningADD176,685$564.5K
Nuveen, LLCNEAR_EXIT140,788$449.8K
IEQ CAPITAL, LLCTRIM116,743$373.0K
Mariner, LLCTRIM74,119$236.8K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

Last action Aug 2026

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Aug 5, 2026Wedbush
MAINTAIN
MAINTAINOutperform
Jun 30, 2026Baird
MAINTAIN
MAINTAINOutperform
May 27, 2026JP Morgan
INITIATE
INITIATEOverweight

Insider ledger

Form 4
$26.1M
bought · 9 insiders
$0
sold · 0 insiders
−39.1%
vs their $4.92 cost
DateInsiderTypeValue
Nov 12, 2026
Hamilton Thomas Edward
Director
Nov 12, 2026
BUY$187.1K
Nov 11, 2026
Truitt Joseph
Director
Nov 11, 2026
BUY$9.8K
Nov 11, 2026
Shankar Gopi
Chief Development Officer
Nov 11, 2026
BUY$13.5K
Nov 11, 2026
Celano Michael
Chief Financial Officer
Nov 11, 2026
BUY$50.0K
Nov 11, 2026
Harlow John B. Jr.
President and COO
Nov 11, 2026
BUY$49.9K
Nov 11, 2026
THOMAS FRANK E
Director
Nov 11, 2026
BUY$21.8K
Nov 11, 2026
BEN-MAIMON CAROLE
President and CEO
Nov 11, 2026
BUY$50.0K
Sep 29, 2026
Harlow John B. Jr.
President and COO
Sep 29, 2026
AWARD800,000 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
10,538,346
shares short
-28.1%
vs prior settlement
8.3
days to cover
≈10.1%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 16, 2026 Earnings
🔒 Fresh data, subscribers only
Nov 12, 2026 SEC
Multiple Larimar Therapeutics insiders, including the CEO, CFO, President/COO, and directors, made open-market…
CLUSTER · Impact 4/10
Nov 12, 2026 Insider
Hamilton Thomas Edward bought 70,000 shares
Director @ $2.67 ($187.1K)
Nov 11, 2026 Insider
Truitt Joseph bought 3,500 shares
Director @ $2.80 ($9.8K)
Nov 11, 2026 Insider
Shankar Gopi bought 5,000 shares
Chief Development Officer @ $2.71 ($13.5K)
Nov 5, 2026 Press
Larimar Therapeutics announced that interim clinical data from its ongoing open-label study of nomlabofusp in…
Impact 2/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
1 drug tracked · Drug pipeline →
Recent

SecBot reports

10 filings · 3 press releases · 7 bullish · 1 bearish · 2 neutral
All LRMR filing & press-release reports (13)